Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Infigratinib - Helsinn/QED Therapeutics

X
Drug Profile

Infigratinib - Helsinn/QED Therapeutics

Alternative Names: BBP-831; BGJ-398; BGJ-398 phosphate; Febseltiq; Infigratinib phosphate; NVP-BGJ398; TRUSELTIQ

Latest Information Update: 28 Jan 2025

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Novartis
  • Developer Array BioPharma; Helsinn; LianBio; Novartis; Novartis Oncology; QED Therapeutics
  • Class Aniline compounds; Antineoplastics; Chlorobenzenes; Methylurea compounds; Phenyl ethers; Piperazines; Pyrimidines; Small molecules
  • Mechanism of Action Type 1 fibroblast growth factor receptor antagonists; Type 3 fibroblast growth factor receptor antagonists; Type 4 fibroblast growth factor receptor antagonists; Type-2 fibroblast growth factor receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Achondroplasia; Cholangiocarcinoma
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Cholangiocarcinoma
  • Phase III Achondroplasia; Bladder cancer; Urogenital cancer
  • Phase II/III Hypochondroplasia
  • Phase II Adenocarcinoma; Gastric cancer; Head and neck cancer; Oesophageal cancer
  • Phase I/II Solid tumours
  • No development reported Breast cancer; Glioma
  • Discontinued Glioblastoma; Haematological malignancies; Malignant melanoma

Most Recent Events

  • 28 Jan 2025 No recent reports of development identified for phase-I development in Bladder-cancer(Neoadjuvant therapy) in USA (PO, Capsule)
  • 24 Jan 2025 Phase-II/III clinical trials in Hypochondroplasia (In children, In adolescents) in USA, United Kingdom, Sweden, Spain, Singapore, Portugal, Norway, France, Canada, Australia (PO) before January 2025 (BridgeBio Pharma pipeline, January 2025) (NCT06410976)
  • 01 Jan 2025 National Cancer Institute terminates a phase I/II trial in Urogenital cancer in USA (PO) as drug manufacturer made the business decision to cease all infigratinib oncology research in the US and withdrew the IND (NCT04228042)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top